Petmed Express (PETS) Gains from Sales and Divestitures (2018 - 2022)

Petmed Express has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $99000.0 in Q1 2022.

• For the quarter ending Q1 2022, Gains from Sales and Divestitures fell 21.43% year-over-year to $99000.0; the trailing twelve-month figure through Mar 2022 stood at $99000.0 (down 21.43% YoY), and the FY2022 full-year result was $99000.0, down 21.43% from the prior year.
• Gains from Sales and Divestitures for Q1 2022 stood at $99000.0, down from $126000.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $126000.0 in Q1 2021, with the low at $114.0 in Q1 2018.
• Historically, Gains from Sales and Divestitures has averaged $82822.8 across 5 years, with a median of $99000.0 in 2022.
• Annual changes were most pronounced in 2019 — Gains from Sales and Divestitures jumped 101654.39% — and 2020, when it tumbled 37.07%.
• Petmed Express' Gains from Sales and Divestitures stood at $114.0 in 2018, then jumped by 101654.39% to $116000.0 in 2019, then plunged by 37.07% to $73000.0 in 2020, then jumped by 72.6% to $126000.0 in 2021, then slipped by 21.43% to $99000.0 in 2022.
• The last three Gains from Sales and Divestitures figures came in at $99000.0 (Q1 2022), $126000.0 (Q1 2021), and $73000.0 (Q1 2020), per Business Quant data.